FibroBiologics, Inc. reported a net loss of $(4.12M) for the quarter ended 2Q 2026, compared with a net loss of $(4.66M) in the year-ago quarter; the company remains pre-revenue with no product sales reported for the period.
Financial Highlights
- Net income: Net loss of $(4.12M) for 2Q 2026, compared with net loss of $(4.66M) in the year-ago quarter — deterioration of $0.54M year-over-year.
- Diluted EPS: Loss per share, basic and diluted $(0.66) for 2Q 2026 vs $(2.41) in the year-ago quarter.
- Revenue: No product revenue reported for the quarter; company remains pre-revenue (no sales disclosed).
Business Highlights
- Clinical progress: Initiated a 12-week Phase 1/2 diabetic foot ulcer (DFU) trial in Australia; interim 6-week data are expected in H2 2026, with final 12-week data anticipated in Q4 2026.
- Pipeline advancement: IND filed for CYPS317 (psoriasis) with the FDA on Dec. 30, 2025; CYMS101 completed a Phase 1 multiple sclerosis study in Mexico showing favorable safety.
- Manufacturing & CMC: Completed master and working cell banks for CYWC628 and produced three cGMP drug-product batches to support the ongoing DFU trial.
- Operational challenges: Patient enrollment has been slower than expected with site resource constraints and extended timelines; the company is recruiting additional sites to improve enrollment.
- Strategic focus & outlook: Management is prioritizing near-term clinical programs, conserving cash by delaying nonessential R&D, and seeking partners to advance the MS and other programs.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.